To conduct a randomized, pragmatic hybrid type 1 effectiveness/implementation multisite (approximately 6 sites) trial to determine whether office-based methadone with pharmacy administration and/or dispensing or office-based buprenorphine results in greater treatment retention in approximately 600 patients with opioid use disorder. This trial will also identify implementation barriers, facilitators and acceptability at the patient, provider and health-systems level for office-based methadone with pharmacy administration and/or dispensing.
Principal Investigator(s)
David Fiellin, M.D.
333 Cedar Street
P.O. Box 208056
New Haven, CT 06520
United States